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THE CAPTOPRIL-DIGOXIN MULTICENTER 
RESEARCH GROUP STUDY ON THE 
COMPARATIVE STEPS OF CAPTOPRIL AND 
DIGOXIN IN PATIENTS WITH MILD- 
MODERATE HEART FAILURE: 
IMPLICATIONS FOR THERAPY 
SUMMARY. It  is argued that the basis of therapy in a patient 
with mild-to-moderate congestive heart failure should be a 
combination of a diuretic and a converting enzyme inhibitor, 
with the further addition of digoxin if necessary. 
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The  therapy of patients with mild-moderate heart 
failure has changed relatively little over the past  
several decades. Although vasodilators and, in par- 
ticular, the converting enzyme inhibitors have been 
shown to be of value in improving exercise performance 
and survival in patients with severe heart failure [1-3], 
they have not found use in the patient  with mild- 
moderate heart  failure. Most patients with mild- 
moderate heart failure, at least in the United States of 
America, are treated with a diuretic alone or with the 
combination of a diuretic and digoxin [4]. The recent 
study on the comparat ive effect of captopril and digox- 
in in patients wit]a mild-moderate heart  failure [5] is 
the first major study to address the issue of the efficacy 
of both of these agents. 
In brief, patient  inclusion criteria were age less than 
75 years, sinus rhythm, left ventricular ejection frac- 
tion of ~<40%, and a treadmill exercise performance less 
than that  predicted for the age and sex, but greater 
than 4 minutes on a modified Naughton protocol, and 
not limited by angina pectoris after withdrawal of 
baseline digoxin and/or vasodilators. Hear t  failure in 
patients solicited for this study was due to either 
ischemic heart disease, primary myocardial disease, or 
to patients  remaining in heart failure without signifi- 
cant valvular regurgitation after valve replacement.  
Four hundred and sixty-four patients met  the entry 
criteria and entered the stabilization period after 
withdrawal from digoxin or vasodilators, and were 
maintained on a stable dose of a diuretic if needed. 
Less than 10% of the patients withdrawn from digoxin 
and/or vasodilators showed any cardiac deterioration, 
such as progressive heart failure, atrial fibrillation, or 
death during the stabilization period. Three hundred 
patients met  the entry criteria and were randomized to 
one of three t rea tment  strategies: captopril 50 mg 
t.i.d., digoxin 0.25 mg q.d., adjusted to a therapeutic 
level by serum digoxin determination, or to placebo. 
All patients were maintained on a diuretic if needed. 
Once in the study, diuretic dosage could be adjusted 
according to patient  symptoms.  Of the 300 patients 
who were randomized into the double-blind study, 83% 
were males, the mean age was 57 years, the mean left 
ventricular ejection fraction was 25%, and the mean 
exercise t ime on a modified Naughton protocol was 560 
seconds. Two thirds of the patients had ischemic heart  
disease and one third had primary myocardial disease. 
The patients were followed with repeat exercise test- 
ing, radioisotope ejection fraction, Holter ECG record- 
ing, and a clinical evaluation for 6 months or until, 
because of symptoms of progressive heart failure, open- 
label therapy with a vasodilator and/or digoxin was 
instituted. 
One of the most important  findings in this study was 
that  patients assigned to the placebo group and main- 
tained on a diuretic alone had significantly more 
episodes of manifest heart failure, as evidenced by 
visits to the emergency room or hospitalization for 
heart failure, compared to either the digoxin- or 
captopril-treated groups. This increased incidence of 
progressive heart failure occurred despite the fact that  
the patients assigned to the placebo group had a 
significantly greater increase in diuretic usage over the 
follow-up period. These data suggest that  maintenance 
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of a patient  with mild-moderate heart failure on a 
diuretic alone is not adequate therapy. Another impor- 
tant  result was the finding that  the patients assigned to 
the captopril group and maintained on a diuretic as 
needed had a significantly greater increase in exercise 
performance and improvement  in functional class than 
the placebo group, while the digoxin group did not. It 
should, however, be pointed out that  the difference in 
exercise performance and functional improvement  be- 
tween captopril and digoxin was not statistically 
significant. There was, however, a significant reduc- 
tion in ventricular ectopic activity in the captopril 
group compared to the digoxin group in patients with 
at least 10 ventricular ectopic beats per hour on their 
baseline Holter ECG. In contrast to these results, the 
patients assigned to the digoxin group had a significant 
increase in their left ventricular ejection fraction com- 
pared to both the captopril and placebo groups. It 
should, however, be emphasized that  in this and pre- 
vious studies [6], there is no significant correlation be- 
tween improvement  in left ventricular ejection fraction 
and improvement  in exercise performance or patient  
well-being. In regards to safety, there was a significant 
increase in hypotension in the captopril group, but 
these episodes were transient, were usually treated by 
decreasing diuretic dosage, and did not result in an in- 
creased drop-out rate compared to the digoxin group. 
The mortali ty rate was calculated at 10.5% per year 
but the power of the study was insufficient to make any 
comments  regarding the relative effects of the treat- 
ment strategies on survival. 
These results and the increasing evidence suggest- 
ing the beneficial effects of vasodilators and, in par- 
ticular, the converting enzyme inhibitors, suggests 
consideration of a new strategy for the t rea tment  of 
patients with mild-moderate heart failure. We propose 
that  patients with mild-moderate heart failure should 
be treated and maintained with a combination of a 
diuretic and a converting enzyme inhibitor. As pointed 
out above, maintenance on a diuretic alone is inade- 
quate to prevent progressive heart failure. Diuretics 
alone tend to st imulate secondary neurohumoral 
mechanisms, including catecholamines, vasopressin, 
and the renin-angiotesin system [7,8]. Diuretic- 
induced activation of the renin-angiotensin system 
results in peripheral as well as coronary vasoconstric- 
tion [9]. Secondly, diuretics when given alone tend to 
cause hypokalemia and hypomagnesemia,  which may 
predispose patients to ventricular arrhythmias  and 
sudden cardiac death [10]. When a diuretic is com- 
bined with a converting enzyme inhibitor, the second- 
ary nuerohumoral activation induced by diuretics is 
blunted and the peripheral and coronary vasoconstric- 
tion is relieved [9]. Similarly, diuretic-induced 
hypokalemia and hypomagnesemia is prevented by 
converting enzyme inhibition. 
Although the combination of a converting enzyme 
inhibitor and a diuretic resulted in a better im- 
provement in exercise performance and functional 
class than digoxin and a diuretic in the multicenter 
study [4], this difference, as pointed out above, is not 
significant. It could, however, be argued that  the study 
design was biased against digoxin, since in order to 
enter the random trial, the patient  had to tolerate 
withdrawal of digoxin and, in fact, approximately 7.5% 
of patients entering the washout period demonstrated 
a need for digoxin and were not randomized. If these 
patients were included, it is possible that  the combina- 
tion of digoxin and a diuretic might be as efficacious as 
the combination of a converting enzyme and a diuretic 
in regard to exercise performance and functional 
class. 
There appears to be little doubt that  digoxin is effec- 
tive in patients with severe heart failure, especially 
those characterized by a dilated left ventricle and the 
presence of a third heart sound [11]. Its role in the 
patient  with mild-moderate heart failure is, however, 
questionable, Several previous studies, including the 
recent German-Aust r ian  study of xamoteroI in over 
300 patients, have failed to show a significant effect of 
digoxin on exercise performance [12]. Even if one 
grants a modest effect on exercise performance and 
patient well-being in patients with mild-moderate 
heart failure receiving digoxin equal to or greater than 
that  seen with captopril and a diuretic, this has to be 
weighed against the potential risk of digitalis toxicity, 
especially in elderly patients, and the uncertain effect 
of digoxin on survival. Several authors have suggested 
that  digoxin might have an adverse effect on survival in 
patients with ischemic heart failure. The studies upon 
which this view is based are, however, retrospective 
and, as pointed out by Yusuf et al. [13], until a prospec- 
tive random trial of digoxin in which mortali ty as the 
endpoint is carried out, no definitive conclusions in 
regard to the risk of digoxin can be reached. However, 
recent animal studies by Lynch et al. [14] in which con- 
scious dogs with an anterior myocardial infarction were 
randomized to digoxin adjusted to the therapeutic 
range or placebo, and were then subjected to ischemia 
of the left circumflex coronary arterial bed, showed an 
increased mortali ty in animals assigned to the digoxin 
group. This study suggests caution in the use of digoxin 
in ischemic heart failure. While it is hazardous to ex- 
trapolate from any animal model to the more complex 
situation in patients with heart failure, it is fair to de- 
mand that  there be a clear benefit to the use of digoxin 
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before one accepts  even the theore t ic  risk of increased 
mor ta l i ty .  Given the available evidence,  it is di f f icul t  
to r e c m o m m e n d  digoxin and a diuret ic  as the sole 
therapy  in the pa t i en t  wi th  mi ld -modera te  heart  
failure. It  should,  however, be emphas i zed  t ha t  if the  
pa t i en t  wi th  m i l d - m o d e r a t e  hear t  fai lure t r ea t ed  with 
a conver t ing enzyme inhib i tor  and  a d iure t ic  remains  
s y m p t o m a t i c ,  then  digoxin should not  be wi thhe ld  and 
may  be of s igni f icant  benefi t .  S imi la r ly ,  in the  pa t i en t  
who cannot  to le ra te  a conver t ing  enzyme inhib i tor  or 
vasod i la t ion  with  isorbide d in i t r a t e  and  hydra laz ine ,  a 
combina t ion  t h a t  has  been shown to be effective in the  
i m p r o v e m e n t  of survival  of pa t i en t s  wi th  hear t  fai lure 
[1], digoxin is ind ica ted .  One could argue for the  use of 
a diuret ic ,  conver t ing  enzyme inhibi tor ,  and  digoxin in 
all pa t i en t s  wi th  m i l d - m o d e r a t e  hear t  fai lure.  If, 
however,  the  pa t i en t  on a d iure t ic  and  conver t ing en- 
zyme inhib i t ion  is a s y m p t o m a t i c  or re la t ive ly  so, there  
would seem to be l i t t le  reason to add  digoxin in 
pa t i en t s  wi th  under ly ing  ischemic hear t  d isease  unt i l  
there  is fur ther  in format ion  on its risk. 
The  s t ra tegy  for the  t he r apy  of pa t i en t s  with mi ld-  
modera t e  hea r t  fai lure ou t l ined  above is in pa r t  based  
upon the  a s sumpt ion  t ha t  the  benefic ia l  effects of con- 
ver t ing  enzyme inh ib i t ion  seen in pa t i en t s  wi th  severe 
hea r t  fai lure [2] will also be ev ident  in the  pa t i en t  wi th  
m i l d - m o d e r a t e  hea r t  fai lure.  W h e t h e r  th is  a s sumpt ion  
is val id  will depend  in pa r t  upon  the  resul ts  of several  
ongoing large prospect ive  t r ia ls ,  inc luding  the  s tudy  of 
left ven t r i cu la r  dysfunc t ion  (SOLVD) and  the  com- 
par i son  of the  effect of conver t ing  enzyme inhib i t ion  to 
the  combina t ion  of isorbide d in i t r a t e  and  hydra laz ine  
on mor t a l i t y  ( V H E F T ) .  Unti l  the resul ts  of  these and 
other ongoing s tudies  are available, it seems  reason- 
able, based upon the ev idence  presen ted  above, to 
r e c o m m e n d  tha t  the basis of  therapy  in the p a t i e n t  
wi th  mi ld -modera te  heart  fa i lure  be a combina t ion  of 
a diuret ic  and a conver t ing  e n z y m e  inhibitor. 
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